<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04626466</url>
  </required_header>
  <id_info>
    <org_study_id>2020-004</org_study_id>
    <secondary_id>2020-A01108-31</secondary_id>
    <nct_id>NCT04626466</nct_id>
  </id_info>
  <brief_title>Measuring the Impact of Low Radiotherapy Doses on Bone Marrow</brief_title>
  <acronym>MIFADORESOL</acronym>
  <official_title>Measuring the Impact of Low Radiotherapy Doses on Bone Marrow</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de cancérologie Strasbourg Europe</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut de cancérologie Strasbourg Europe</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bone marrow is one of the organs at risk of complications during irradiation due to its&#xD;
      radiosensitivity. Hematopoietic toxicity remains one of the main toxicities during&#xD;
      irradiation of pelvic lymph node areas, especially when concomitant chemotherapy is used,&#xD;
      volume of bone marrow irradiated is large and dose to the bone marrow is high. There is a&#xD;
      lack of prospective studies and comparative trials to customize the constraints according to&#xD;
      the presence or absence of chemotherapy and correlated to the patient's bone marrow&#xD;
      potential. This monocentric and prospective study conducted by Strasbourg Europe Cancerology&#xD;
      Institute aims to evaluate hematological toxicity (anemia, thrombocytopenia, leukopenia) in&#xD;
      patients treated with pelvic irradiation for prostate, rectum, anal canal, endometrium, or&#xD;
      cervix cancer. One hundred patients will be included in the study, including patients treated&#xD;
      with exclusive radiotherapy, radiochemotherapy, or radiohormonal therapy. The primary&#xD;
      objective is to quantify the relationship between acute hematological toxicity and delivered&#xD;
      doses and irradiated volumes in pelvic bone marrow for pelvic cancers. Hematological toxicity&#xD;
      will be measured by weekly blood count during radiotherapy and at one month and three months&#xD;
      after the end of radiotherapy. Secondary endpoints are the evaluation of viral, bacterial and&#xD;
      fungal infections during and for three months following radiotherapy, as well as the&#xD;
      evaluation of the impact of radiation-induced hematological toxicity on the administration of&#xD;
      chemotherapy for the concerned patients. The aim of this study is to improve and optimize&#xD;
      radiotherapy if a dose limit or volume constraint is imposed by the results of the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients will be identified as potentially eligible for inclusion once radiotherapy has been&#xD;
      decided upon at the multidisciplinary consultation meeting. During the radiotherapy&#xD;
      consultation, the study will be offered to the patient if they also meet the other inclusion&#xD;
      criteria. As soon as the consent is signed and before the first radiotherapy session, a first&#xD;
      biological check-up including a blood count and renal function will be performed. This&#xD;
      biological investigation will serve as a reference.&#xD;
&#xD;
      During the dosimetric computer-tomography scan for radiotherapy, bony structures will be&#xD;
      delineated, iliac bones, lower pelvis, femoral heads, lumbosacral spine and entire pelvis.&#xD;
&#xD;
      Dosimetry will be performed in the same way whether patients are included in the study or&#xD;
      not, they will receive between 25Gy in 5 fractions and 78Gy in 39 fractions, depending on the&#xD;
      primary tumor. The dose volume histograms will be received.&#xD;
&#xD;
      During treatment, patients will have a weekly blood test starting from the second week of&#xD;
      treatment. At one months and three months after the end of the radiotherapy, patients will be&#xD;
      seen in consultation and will also have a blood test.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 3, 2020</start_date>
  <completion_date type="Anticipated">March 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of acute haematological toxicity according to CTCAE v5.0</measure>
    <time_frame>throughout radiotherapy treatment</time_frame>
    <description>Haemoglobin&#xD;
Platelets&#xD;
Neutrophils&#xD;
Lymphocytes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of acute haematological toxicity according to CTCAE v5.0</measure>
    <time_frame>1 month after the end of radiotherapy</time_frame>
    <description>Haemoglobin&#xD;
Platelets&#xD;
Neutrophils&#xD;
Lymphocytes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of acute haematological toxicity according to CTCAE v5.0</measure>
    <time_frame>3 months after the end of radiotherapy</time_frame>
    <description>Haemoglobin&#xD;
Platelets&#xD;
Neutrophils&#xD;
Lymphocytes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with clinical signs of viral, bacterial, or fungal infections according to CTCAE v5.0</measure>
    <time_frame>throughout treatment, at 1 and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients undergoing definitive and transient discontinuations of concomitant chemotherapy.</measure>
    <time_frame>throughout treatment, at 1 and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients who required a reduction in chemotherapy dose.</measure>
    <time_frame>throughout treatment, at 1 and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative doses and theoretical doses of chemotherapy.</measure>
    <time_frame>throughout treatment, at 1 and 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients undergoing definitive withdrawal or transitory stops of the entire treatment.</measure>
    <time_frame>throughout treatment, at 1 and 3 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Prostate Carcinoma</condition>
  <condition>Rectum Carcinoma</condition>
  <condition>Anal Canal Carcinoma</condition>
  <condition>Endometrium Carcinoma</condition>
  <condition>Cervix Carcinoma</condition>
  <condition>Radiotherapy</condition>
  <arm_group>
    <arm_group_label>Non-metastatic prostate, rectum, anal canal, endometrium, or cervix carcinoma Radiotherapy treatment</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Biological investigations</intervention_name>
    <description>(complete blood count, platelet count, renal function evaluation)</description>
    <arm_group_label>Non-metastatic prostate, rectum, anal canal, endometrium, or cervix carcinoma Radiotherapy treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Non-metastatic prostate, rectum, anal canal, endometrium, or cervix carcinoma Radiotherapy&#xD;
        treatment validated in a multidisciplinary consultation meeting&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        For inclusion in the study, patients must be affiliated to the national or local social&#xD;
        security, and must meet all the following criteria :&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must be ≥ 18 years old and &lt; 70 years old (&lt; 80 years old for patients with&#xD;
             prostate cancer)&#xD;
&#xD;
          -  Performance Status 0 to 2&#xD;
&#xD;
          -  Histologically-confirmed diagnosis of : prostate cancer ; cervical cancer ;&#xD;
             endometrial cancer ; middle or low rectal cancer ; anal duct carcinoma&#xD;
&#xD;
          -  At inclusion, patients must have : Haemoglobin &gt; 10 g/dL ; Leucocytes 4.0-11.0 g/L ;&#xD;
             Neutrophils 1.5-7.7 g/L ; Platelets 150-400 g/L&#xD;
&#xD;
          -  Signed informed consent from the patient&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of haematologic disorders, leucopathia or imune system diseases&#xD;
&#xD;
          -  At inclusion, patients must not have : Haemoglobin &lt; 10 g/dL or &gt; 18 g/dL (men) &gt; 16&#xD;
             g/dL (women) ; Leucocytes &lt; 4.0 or &gt; 11.0 g/L ; Neutrophils &lt; 1.5 or &gt; 7.7 g/L ;&#xD;
             Platelets &lt; 150 or &gt; 400 g/L&#xD;
&#xD;
          -  Patients previously treated with radiation therapy or with chemotherapy&#xD;
&#xD;
          -  Patients with metastatic cancer&#xD;
&#xD;
          -  Patients presenting tumor classified histologically as sarcomatoid&#xD;
&#xD;
          -  Patients placed under judicial protection, guardianship, or supervision&#xD;
&#xD;
          -  Women that are pregnant or breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>79 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Valérie SARTORI</last_name>
    <phone>368767223</phone>
    <phone_ext>33</phone_ext>
    <email>v.sartori@icans.eu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Manon VOEGELIN, PhD</last_name>
    <phone>368767360</phone>
    <phone_ext>33</phone_ext>
    <email>promotion-rc@icans.eu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancerologie Strasbourg Europe</name>
      <address>
        <city>Strasbourg</city>
        <zip>67033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valérie SARTORI</last_name>
      <phone>368767223</phone>
      <phone_ext>33</phone_ext>
      <email>v.sartori@icans.eu</email>
    </contact>
    <contact_backup>
      <last_name>Manon VOEGELIN</last_name>
      <phone>368767360</phone>
      <phone_ext>33</phone_ext>
      <email>m.voegelin@icans.eu</email>
    </contact_backup>
    <investigator>
      <last_name>Georges NOEL, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laure KUNTZ</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Audrey KELLER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Clara LE FEVRE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Inès MENOUX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gian Andrea PIETTA, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Catherine SCHUMACHER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 3, 2020</study_first_submitted>
  <study_first_submitted_qc>November 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 12, 2020</study_first_posted>
  <last_update_submitted>November 10, 2020</last_update_submitted>
  <last_update_submitted_qc>November 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bone marrow</keyword>
  <keyword>Hematologic toxicity</keyword>
  <keyword>Pelvic irradiation</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Intensity-modulated radiotherapy (IMRT)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

